This article is a correction to:
A randomized controlled trial to examine the impact of a multi-strain probiotic on self-reported indicators of depression, anxiety, mood, and associated biomarkers
Kylie E. Walden1
Jessica M. Moon1†
Anthony M. Hagele1†Leah E. Allen1Connor J. Gaige1
Joesi M. Krieger1
Ralf Jäger2
Petey W. Mumford1
Marco Pane3
Chad M. Kerksick1*†- 1Exercise and Performance Nutrition Laboratory, Department of Kinesiology, College of Science, Technology, and Health, Lindenwood University, Saint Charles, MO, United States
- 2Increnovo LLC, Milwaukee, WI, United States
- 3Probiotical srl, Novara, Italy
by Walden, K. E., Moon, J. M., Hagele, A. M., Allen, L. E., Gaige, C. J., Krieger, J. M., Jager, R., Mumford, P. W., Pane, M., and Kerksick, C. M. (2023). Front. Nutr. 10:1219313. doi: 10.3389/fnut.2023.1219313
In the published article, there was an error. The viability results of the provided probiotic did not include reference to the live cell viability assessments that were also completed.
A correction has been made to the Abstract. This sentence previously stated:
“In a randomized, double-blind, placebo-controlled fashion, 70 healthy men and women (31.0 ± 9.5 years, 173.0 ± 10.4 cm, 73.9 ± 13.8 kg, 24.6 ± 3.5 kg/m2) supplemented with a single capsule of MSP (a total daily dose of 4 x 109 colony forming units [CFU] comprised of a 1 x 109 CFU dose from each of the following strains: Limosilactobacillus fermentum LF16, Lacticaseibacillus rhamnosus LR06, Lactiplantibacillus plantarum LP01, and Bifidobacterium longum 04, Probiotical S.p.A., Novara, Italy) or a maltodextrin placebo (PLA).”
The corrected sentence appears below:
“In a randomized, double-blind, placebo-controlled fashion, 70 healthy men and women (31.0 ± 9.5 years, 173.0 ± 10.4 cm, 73.9 ± 13.8 kg, 24.6 ± 3.5 kg/m2) supplemented with a single capsule of MSP (a total daily dose of 4 × 109 live cells comprised of a 1 × 109 live cells dose from each of the following strains: Limosilactobacillus fermentum LF16, Lacticaseibacillus rhamnosus LR06, Lactiplantibacillus plantarum LP01, and Bifidobacterium longum 04, Probiotical S.p.A., Novara, Italy) or a maltodextrin placebo (PLA).”
In the published article, there was an error. The viability results of the provided probiotic did not include reference to the live cell viability assessments that were also completed. We also failed to specify composition of the placebo.
A correction has been made to the Abstract. This sentence previously stated:
“They either received a multi-strain probiotic (1 x 109 CFU of each of the four strains: Limosilactobacillus fermentum LF16 (DSM 26956), Lacticaseibacillus rhamnosus LR06 (DSM 21981), Lactiplantibacillus plantarum LP01 (LMG P-21021), and Bifidobacterium longum 04 (DSM 23233); Probiotical S.p.A., Novara, Italy) or a placebo (PLA).”
The corrected sentence appears below:
“The probiotic formulation (MSP) administered during the study was a blend of the four strains: Lactiplantibacillus plantarum LP01 (LMG P-21021), Limosilactobacillus fermentum LF16 (DSM 26956), Lacticaseibacillus rhamnosus LR06 (DSM 21981), and Bifidobacterium longum 04 (DSM 23233) blended with maltodextrin (2.5 g) all belonging to Probiotical S.P.A. collection. The clinical formula had a cell potency measured by Plate Count of >4 × 109 Colony Forming Units (CFU)/dose. (Biolab Research Method 014-06). Cell potency of the samples was also measured by flow cytometer (ISO 19344:2015 IDF 232:2015) resulting in values of >4 × 109 Active Fluorescent Units (AFU)/dose. The probiotic formulation was referred to 4 × 109 live cells/dose. Placebo (PLA) was composed of pure maltodextrins (2.5 g).”
In the published article, there was an error. The viability results of the provided probiotic did not include reference to the live cell viability assessments that were also completed.
A correction has been made to the Abstract. This sentence previously stated:
“Each probiotic dose was delivered in capsules containing a 1 × 109 colony forming units (CFU) dose of each of the following strains (total daily dose of 4 × 109 CFU): Limosilactobacillus fermentum LF16 (DSM 26956), Lacticaseibacillus rhamnosus LR06 (DSM21981), Lactiplantibacillus plantarum LP01 (LMG P-21021), and Bifidobacterium longum 04 (DSM 23233) (Probiotical S.p.A., Novara, Italy).”
The corrected sentence appears below:
“Each probiotic dose was delivered in capsules containing a 1 × 109 live cells dose of each of the following strains (total daily dose of 4 × 109 live cells): Limosilactobacillus fermentum LF16 (DSM 26956), Lacticaseibacillus rhamnosus LR06 (DSM21981), Lactiplantibacillus plantarum LP01 (LMG P-21021), and Bifidobacterium longum 04 (DSM 23233) (Probiotical S.p.A., Novara, Italy).”
In the published article, there was an error. The viability results of the provided probiotic did not include reference to the live cell viability assessments that were also completed.
A correction has been made to the Abstract. This sentence previously stated:
“The finished supplementation product was analyzed (Biolab srl, Novara, Italy) via flow cytometry (ISO 19344, 2015: IDF 232: 2015) upon batch release which resulted in a cell count of >4 × 109 Active Fluorescent Unit (AFU)/g and plate count method as colony forming units (CFU) (Internal Method 014–06)”
The corrected sentence appears below:
“MSP was analyzed via plate count method as colony forming units (CFU) (Internal Method 014–06) and flow cytometry (ISO 19344, 2015: IDF 232: 2015) as Active Fluorescent Units (AFU) upon batch release (Biolab srl, Novara, Italy).”
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: probiotic, gut-brain, quality of life, mood, serotonin
Citation: Walden KE, Moon JM, Hagele AM, Allen LE, Gaige CJ, Krieger JM, Jäger R, Mumford PW, Pane M and Kerksick CM (2023) Corrigendum: A randomized controlled trial to examine the impact of a multi-strain probiotic on self-reported indicators of depression, anxiety, mood, and associated biomarkers. Front. Nutr. 10:1324536. doi: 10.3389/fnut.2023.1324536
Received: 19 October 2023; Accepted: 07 November 2023;
Published: 21 November 2023.
Edited and reviewed by: Yashi Mi, University of Arizona, United States
Copyright © 2023 Walden, Moon, Hagele, Allen, Gaige, Krieger, Jäger, Mumford, Pane and Kerksick. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Chad M. Kerksick, ckerksick@lindenwood.edu
†ORCID: Jessica M. Moon orcid.org/0000-0003-4702-3077
Anthony M. Hagele orcid.org/0000-0002-5575-3670
Chad M. Kerksick orcid.org/0000-0003-0458-7294